Deng, LD

Dong, AJ

Huang, Y

Qiao, Y

Qiu, C

Wan, YM

Xing, JF

Xu, JQ

Yuan, SH

Yue, XY

Zhang, CY

Retrovirology

English

PubMed

Y Qiao

Y Huang

XY Yue

C Qiu

LD Deng

YM Wan

JF Xing

CY Zhang

SH Yuan

AJ Dong

JQ Xu

Crossref

P11-04. PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as mucosal DNA delivery vector improves HIV-1-specific immune responses

Springer - Publisher Connector

BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessPoster presentation
P11-04. PEGylated poly [2-(N,N-dimethylamino) ethyl 
methacrylate] as mucosal DNA delivery vector improves 
HIV-1-specific immune responses
Y Qiao1, Y Huang*2, XY Yue1, C Qiu2, LD Deng1, YM Wan2, JF Xing1, 
CY Zhang2, SH Yuan2, AJ Dong1 and JQ Xu2
Address: 1Tianjin University, Tianjin, PR China and 2Science Research Center, Shanghai Public Health Clinical Center, Shanghai, PR China
* Corresponding author    
Background
Development of safe and efficient vectors is crucial for
gene therapy and vaccine delivery. As a promising trans-
fection reagent, poly [2-(N,N-dimethylamino) ethyl
methacrylate] (PDMAEMA) have potential applications in
gene delivery systems. However, its high cytotoxicity lim-
its its advances into clinical evaluation. Polyethylene gly-
col (PEG) is one of the most widely used to decrease
polymers' cytotoxicity in drug delivery systems. But the
vaccine delivery effects was still unclear by PEGylation for
this polymer.
Methods
PEGylated PDMAEMA was synthesized with PEG seg-
ments by atom transfer radical polymerization, and its
binding capability to DNA was determinded by gel elec-
trophore retardation assaysis. Its effects on transfection
efficiency and cytotoxicity in vitro were determined by
Flow Cytometry using GFP as a reporter and MTT assay
respectivly. Finally, ELISA and Elispot assay were used to
evaluated its effects on immunogenicity as a mucosal
DNA vaccine carrier in vivo. An plasmid DNA expressing
HIV-1 gag was used as an model vaccine.
Results
PEGylated PDMAEMA retained its DNA bing capability
and its cytotoxicity was dramatically decreased compared
to unPEGylated PDMAEMA but with low transfection effi-
ciency in vitro. However, our in vivo data proved that
PEGylated PDMAEMA significantly improved the priming
effect of an HIV DNA vaccine through intranasal adminis-
tration compared to another cation vector polyethylene-
imine (PEI) and had more immunositmulatory ability in
vitro.
Conclusion
Our study suggested that PEGylated PDMAEMA could be
used in vaccine research as a nonviral vector and impor-
tantly, transfection efficiency in vitro did not correlate to
the immunogenicity in vivo for polymer vectors especially
due to its potential adjuvant effects.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P149 doi:10.1186/1742-4690-6-S3-P149
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P149
© 2009 Qiao et al; licensee BioMed Central Ltd. 


https://retrovirology.biomedcentral.com/track/pdf/10.1186/1742-4690-6-S3-P149?site=retrovirology.biomedcentral.com

P11-04. PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as mucosal DNA delivery vector improves HIV-1-specific immune responses

Abstract

Similar works

Full text

Available Versions

Crossref

Springer - Publisher Connector